Efficacy of letermovir in HLA-haploidentical hematopoietic transplantation with posttransplant cyclophosphamide.

[1]  K. Akashi,et al.  Risk factors for late cytomegalovirus infection after completing letermovir prophylaxis , 2022, International Journal of Hematology.

[2]  E. Shpall,et al.  Refractory and Resistant Cytomegalovirus after Hematopoietic Cell Transplant in the Letermovir Primary Prophylaxis Era. , 2021, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[3]  M. Perales,et al.  Post-Transplant Cyclophosphamide (PTCy) is Associated with Increased Cytomegalovirus Infection: A CIBMTR Analysis. , 2021, Blood.

[4]  T. Luft,et al.  Letermovir prophylaxis is effective in preventing cytomegalovirus reactivation after allogeneic hematopoietic cell transplantation: single-center real-world data , 2020, Annals of Hematology.

[5]  K. Akashi,et al.  Efficacy of prophylactic letermovir for cytomegalovirus reactivation in hematopoietic cell transplantation: a multicenter real-world data , 2020, Bone Marrow Transplantation.

[6]  Ji Lin,et al.  Risk factors and associations with clinical outcomes of cytomegalovirus reactivation after haploidentical versus matched-sibling unmanipulated PBSCT in patients with hematologic malignancies , 2020, Annals of Hematology.

[7]  N. Kröger,et al.  Haploidentical Stem Cell Transplantation With Posttransplant Cyclophosphamide Therapy vs Other Donor Transplantations in Adults With Hematologic Cancers: A Systematic Review and Meta-analysis. , 2019, JAMA oncology.

[8]  H. Chu,et al.  HLA-haploidentical vs matched-sibling hematopoietic cell transplantation: a systematic review and meta-analysis. , 2019, Blood advances.

[9]  A. A. Ribeiro,et al.  Haploidentical Transplantation with Post-Transplant Cyclophosphamide versus Unrelated Donor Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-Analysis. , 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[10]  B. Sandmaier,et al.  Outcomes of haploidentical vs matched sibling transplantation for acute myeloid leukemia in first complete remission. , 2019, Blood advances.

[11]  H. Einsele,et al.  Haploidentical versus unrelated allogeneic stem cell transplantation for relapsed/refractory acute myeloid leukemia: a report on 1578 patients from the Acute Leukemia Working Party of the EBMT , 2018, Haematologica.

[12]  R. Vij,et al.  Cytomegalovirus viremia, disease, and impact on relapse in T-cell replete peripheral blood haploidentical hematopoietic cell transplantation with post-transplant cyclophosphamide , 2016, Haematologica.

[13]  M. Norkin,et al.  Early cytomegalovirus reactivation remains associated with increased transplant-related mortality in the current era: a CIBMTR analysis. , 2016, Blood.

[14]  H. Einsele,et al.  Donor cytomegalovirus status influences the outcome of allogeneic stem cell transplant: a study by the European group for blood and marrow transplantation. , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[15]  M. Horowitz,et al.  Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation. , 2014, Blood.

[16]  Y. Kanda,et al.  Investigation of the freely available easy-to-use software ‘EZR' for medical statistics , 2012, Bone Marrow Transplantation.

[17]  Allen R. Chen,et al.  HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. , 2008, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[18]  M. Sorror,et al.  Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. , 2005, Blood.

[19]  K. Matsuo,et al.  Allogeneic hematopoietic stem cell transplantation from family members other than HLA-identical siblings over the last decade (1991-2000). , 2003, Blood.

[20]  M. Leffell,et al.  Nonmyeloablative bone marrow transplantation from partially HLA-mismatched related donors using posttransplantation cyclophosphamide. , 2002, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[21]  K. Takenaka,et al.  Increased incidence of cytomegalovirus (CMV) infection and CMV-associated disease after allogeneic bone marrow transplantation from unrelated donors , 1997, Bone Marrow Transplantation.